JP7706456B2 - Ｓｍａｒｃａ２－ｖｈｌ分解剤 - Google Patents

Ｓｍａｒｃａ２－ｖｈｌ分解剤 Download PDF

Info

Publication number
JP7706456B2
JP7706456B2 JP2022541815A JP2022541815A JP7706456B2 JP 7706456 B2 JP7706456 B2 JP 7706456B2 JP 2022541815 A JP2022541815 A JP 2022541815A JP 2022541815 A JP2022541815 A JP 2022541815A JP 7706456 B2 JP7706456 B2 JP 7706456B2
Authority
JP
Japan
Prior art keywords
mmol
cancer
amino
piperazin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022541815A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021142247A5 (https=
JP2023510746A (ja
JP2023510746A5 (https=
Inventor
バナジー，アビシェク
シー，ビクター・ジェイ
チェン，ニン
リ，シャオフェン
ブルツ，ライアン・ポール
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2023510746A publication Critical patent/JP2023510746A/ja
Publication of JPWO2021142247A5 publication Critical patent/JPWO2021142247A5/ja
Publication of JP2023510746A5 publication Critical patent/JP2023510746A5/ja
Application granted granted Critical
Publication of JP7706456B2 publication Critical patent/JP7706456B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022541815A 2020-01-10 2021-01-08 Ｓｍａｒｃａ２－ｖｈｌ分解剤 Active JP7706456B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959502P 2020-01-10 2020-01-10
US62/959,502 2020-01-10
PCT/US2021/012683 WO2021142247A1 (en) 2020-01-10 2021-01-08 Smarca2-vhl degraders

Publications (4)

Publication Number Publication Date
JP2023510746A JP2023510746A (ja) 2023-03-15
JPWO2021142247A5 JPWO2021142247A5 (https=) 2024-01-16
JP2023510746A5 JP2023510746A5 (https=) 2024-01-16
JP7706456B2 true JP7706456B2 (ja) 2025-07-11

Family

ID=74495106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022541815A Active JP7706456B2 (ja) 2020-01-10 2021-01-08 Ｓｍａｒｃａ２－ｖｈｌ分解剤

Country Status (7)

Country Link
US (1) US20230091042A1 (https=)
EP (1) EP4087658A1 (https=)
JP (1) JP7706456B2 (https=)
AU (1) AU2021205326A1 (https=)
CA (1) CA3167166A1 (https=)
MX (1) MX2022008487A (https=)
WO (1) WO2021142247A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
WO2022029617A1 (en) * 2020-08-04 2022-02-10 Aurigene Discovery Technologies Limited 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
EP4259144A4 (en) * 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
US11993599B2 (en) 2021-08-09 2024-05-28 Genentech, Inc. Therapeutic compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019123367A1 (en) 2017-12-21 2019-06-27 Astrazeneca Ab Compounds and their use in treating cancer
WO2019207538A1 (en) 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190300521A1 (en) * 2018-04-01 2019-10-03 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019123367A1 (en) 2017-12-21 2019-06-27 Astrazeneca Ab Compounds and their use in treating cancer
WO2019207538A1 (en) 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)

Also Published As

Publication number Publication date
MX2022008487A (es) 2022-08-02
US20230091042A1 (en) 2023-03-23
EP4087658A1 (en) 2022-11-16
AU2021205326A1 (en) 2022-07-21
WO2021142247A1 (en) 2021-07-15
JP2023510746A (ja) 2023-03-15
CA3167166A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
JP7706456B2 (ja) Ｓｍａｒｃａ２－ｖｈｌ分解剤
AU2011205302B2 (en) Voltage-gated sodium channel blockers
US11572374B2 (en) N-cyano-7-azanorbornane derivatives and uses thereof
CA3093851A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
IL322853A (en) History of 1-(([1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-n-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide as ras-pi3k modulators for exemplary cancer therapy
JP2013507350A (ja) カルシウム放出依存性カルシウムチャネルのモジュレータとしてのピラゾール誘導体
JP2011522865A (ja) Ｉａ心不全および癌の治療に有用なプロテインキナーゼｄ阻害剤としての２，４’−ビピリジニル化合物
KR20150033652A (ko) 보체 경로 조절제 및 그의 용도
NZ509310A (en) N,N-substituted cyclic amine derivatives as calcium channel antagonists
JP2019507179A (ja) Ｗｄｒ５タンパク質−タンパク質結合の阻害剤
AU2014274354A1 (en) Dihydropyridinone MGAT2 inhibitors
KR20160120790A (ko) 대사 장애의 치료에 사용하기 위한 디히드로피리디논 mgat2 억제제
KR102441864B1 (ko) 괴사의 억제제로서 헤테로아릴 화합물, 이의 조성물 및 이의 용도
JP2023516102A (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物、およびそれを含む医薬組成物
JP7726591B2 (ja) ボロン酸化合物
US20140121213A1 (en) Voltage-gated sodium channel blockers
CN114466844A (zh) N-(1h-咪唑-2-基)苯甲酰胺化合物及包含其作为活性成分的药物组合物
US8993557B2 (en) Pyridinedione carboxamide inhibitors of endothelial lipase
JP2021529772A (ja) アミノ−ピリミドニル誘導体、その調製プロセス及びそれを含有する医薬組成物
TW201441193A (zh) 吡啶酮化合物
CN103781765A (zh) 作为hdl-胆固醇升高剂的3-吡啶甲酰肼类
US10597370B2 (en) 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors
HK40105619A (zh) 包括氮杂环丁烷环脲的rip1调节剂、其制备和用途
HK40046935A (en) Amino-pyrimidonyl derivatives, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250701

R150 Certificate of patent or registration of utility model

Ref document number: 7706456

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150